For the NHS
For business
Solutions
Science
Clinicians
Investors
About Us
Careers
Get in touch
FacebookTwitterLinkedinYouTube

Dr Andrew Welchman

Senior Leadership Team

Andrew is our Executive Vice President for Impact. He joined ieso in 2021 to help us harness our scientific breakthroughs and clinical learnings to transform global mental healthcare at scale.

Working alongside our Chief Scientific Officer, Andy Blackwell, he is responsible for forging strategic alliances with a wide range of organisations to collaborate on ground-breaking research and accelerate innovation and the adoption of new breakthroughs.

The significant advances being made in data science at ieso are set to transform the delivery of mental health and Andrew will be instrumental in amplifying our success to date.

As Head of Neuroscience and Mental Health at the Wellcome Trust, Dr Welchman led strategic initiatives for a £500m portfolio in cutting-edge brain science. He developed the multi-million-pound initiative in Mental Health Science that has become central to Wellcome’s ambitions for the next two decades.

As Professor of Neural Intelligence at the University of Cambridge, Andrew and his team combined advanced human brain imaging and AI to uncover how we perceive and understand the world around us. He is a Fellow of the Royal Society of Biology, has worked closely with several Royal Colleges (Royal College of Psychiatry; Royal College of Ophthalmology), and has been an advisor for large-scale international research efforts, collaborative partnerships (The India Alliance), The World Economic Forum and charities (BBC Children in Need).

“We know that poor mental health is an urgent and global problem – but we now need actions to meet the challenge. I have long admired ieso’s innovative data-driven approach to mental healthcare that shows how rigorous science improves treatment quality and delivers results for people suffering from mental health conditions. Tectonic shifts in technology mean we are primed to make quality care available for all. We are determined to drive change to reduce suffering so that millions of people around the globe lead flourishing lives.”

Dr Nigel Pitchford

Chief Executive Officer

Dr Valentin Tablan

Chief Artificial Intelligence Officer

Dr Andy Blackwell

Group Chief Science & Strategy Officer

Dr Andy Blackwell

Group Chief Science & Strategy Officer

Stephen Freer

EVP Clinical

Dr Charlotte Housden

Chief Operating Officer

Michael Black

Chief Financial Officer

Dani Smallbone

Chief Marketing Officer

Kate Woolland

Chief Partnerships Officer

James Kellerman

Chief Technology Officer

Dr Valentin Tablan

Chief Artificial Intelligence Officer

Dr Jennifer Gentile

SVP US Clinical Operations

Lynn Lakey

Interim Managing Director

Chris Kightley

Interim Managing Director

Dr Andrew Welchman

Executive Vice President for Impact

Danah Tangen

Chief of Staff